ProQR Therapeutics N.V.

PRQR

$2.05

Name : ProQR Therapeutics N.V.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $215,957,632.00

EPSttm : -0.48

ProQR Therapeutics N.V.

$2.05

5.53%

$0.12

Float Short %

1.11

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.11

EPS This/Next Y

-0.13

Price

2.05

Target Price

9.02

Analyst Recom

Performance Q

0.99

Relative Volume

0.66

Beta

0.22

Ticker: PRQR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	PRQR	3.05	0.02	0.14	13227
2025-10-21	PRQR	2.94	0.05	0.00	14747
2025-10-22	PRQR	2.73	0.05	0.00	15073
2025-10-23	PRQR	2.82	0.05	0.10	15138
2025-10-24	PRQR	2.94	0.05	0.00	15323
2025-10-27	PRQR	2.84	0.05	0.00	15337
2025-10-28	PRQR	2.86	0.05	0.01	15538
2025-10-29	PRQR	2.65	0.05	0.00	15543
2025-10-30	PRQR	2.72	0.05	0.00	15586
2025-10-31	PRQR	2.73	0.05	0.00	15911
2025-11-03	PRQR	2.61	0.04	4.33	16209
2025-11-04	PRQR	2.38	0.05	0.00	16292
2025-11-05	PRQR	2.37	0.05	0.01	16289
2025-11-06	PRQR	2.21	0.05	0.00	16374
2025-11-07	PRQR	2.19	0.05	0.00	16377
2025-11-10	PRQR	2.16	0.05	0.00	16373
2025-11-11	PRQR	2.16	0.05	0.00	16377
2025-11-12	PRQR	2.14	0.05	29.33	16427
2025-11-13	PRQR	2.15	0.05	0.00	16429
2025-11-14	PRQR	2.17	0.05	0.00	16924
2025-11-17	PRQR	2.05	0.04	0.00	18425
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	PRQR	3.05	-117.4	-	-0.47
2025-10-21	PRQR	2.94	-117.4	-	-0.47
2025-10-22	PRQR	2.72	-117.4	-	-0.47
2025-10-23	PRQR	2.83	-117.4	-	-0.47
2025-10-24	PRQR	2.91	-117.4	-	-0.47
2025-10-27	PRQR	2.83	-117.4	-	-0.47
2025-10-28	PRQR	2.85	-117.4	-	-0.47
2025-10-29	PRQR	2.65	-117.4	-	-0.47
2025-10-30	PRQR	2.72	-117.4	-	-0.47
2025-10-31	PRQR	2.75	-117.4	-	-0.47
2025-11-03	PRQR	2.60	-117.4	-	-0.47
2025-11-04	PRQR	2.38	-117.4	-	-0.47
2025-11-05	PRQR	2.38	-117.4	-	-0.47
2025-11-06	PRQR	2.21	-117.4	-	-0.47
2025-11-07	PRQR	2.22	-117.4	-	-0.47
2025-11-10	PRQR	2.16	-61.4	-	-0.47
2025-11-11	PRQR	2.16	-61.4	-	-0.47
2025-11-12	PRQR	2.14	-61.4	-	-0.47
2025-11-13	PRQR	2.15	-61.4	-	-0.47
2025-11-14	PRQR	2.16	-	-	-0.51
2025-11-17	PRQR	2.05	-	-	-0.48
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	PRQR	0.00	0.67	1.68
2025-10-21	PRQR	0.00	0.67	1.68
2025-10-22	PRQR	0.00	0.67	1.68
2025-10-23	PRQR	0.00	0.67	1.68
2025-10-24	PRQR	0.00	0.67	1.68
2025-10-27	PRQR	0.00	0.62	3.02
2025-10-28	PRQR	0.00	0.62	3.02
2025-10-29	PRQR	0.00	0.62	3.02
2025-10-30	PRQR	0.00	0.62	3.02
2025-10-31	PRQR	0.00	0.62	3.02
2025-11-03	PRQR	0.00	0.58	3.02
2025-11-04	PRQR	0.00	0.58	3.02
2025-11-05	PRQR	0.00	0.58	3.02
2025-11-06	PRQR	0.00	0.58	3.02
2025-11-07	PRQR	0.00	0.58	3.02
2025-11-10	PRQR	0.00	-0.80	3.02
2025-11-11	PRQR	0.00	-0.80	3.02
2025-11-12	PRQR	0.00	-0.80	1.12
2025-11-13	PRQR	0.00	-0.80	1.12
2025-11-14	PRQR	0.00	-0.80	1.12
2025-11-17	PRQR	0.00	-0.80	1.11
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.12

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

-0.8

Beta

0.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

78.3

Max Drawdown 5-Year %

-93.9

Target Price

9.02

P/E

Forward P/E

PEG

P/S

12.65

P/B

3.22

P/Free Cash Flow

EPS

-0.46

Average EPS Est. Cur. Y

-0.48

EPS Next Y. (Est.)

-0.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-276.92

Relative Volume

0.66

Return on Equity vs Sector %

-101.5

Return on Equity vs Industry %

-86.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

ProQR Therapeutics N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 166

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

stock quote shares PRQR – ProQR Therapeutics N.V. Stock Price stock today

news today PRQR – ProQR Therapeutics N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch PRQR – ProQR Therapeutics N.V. yahoo finance google finance

stock history PRQR – ProQR Therapeutics N.V. invest stock market

stock prices PRQR premarket after hours

ticker PRQR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PRQR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y